Bristol Myers schizophrenia therapy safe in late-stage trial Markets April 6, 2024 [ad_1] hapabapa/iStock Editorial through Getty Pictures Bristol Myers Squibb (NYSE:BMY) introduced Saturday that its experimental schizophrenia remedy KarXT, acquired as…
